_single-cell-profiling-reveals-key-differences-in-architecture-of-stem-and-progenitor-cells-throughout-life.jpg "Single cell profiling reveals key differences in architecture of stem and progenitor cells throughout life from erythroid Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 3 min 78 sec
✓ Published: 16-Jun-2018
✓ Published: 16-Jun-2018
Description:
Dr Roy speaks with ecancer at EHA 23 about observed changes in blood stem cells over at different stages of development, from infancy to adulthood.nnShe describes how, starting from matched liver and bone marrow samples, changes in erythroid, myeloid and lymphoid progenitor cell populations can be charted, and differences between samples indicate a driver of differentiation in the microenvironment.
Dr Roy speaks with ecancer at EHA 23 about observed changes in blood stem cells over at different stages of development, from infancy to adulthood.nnShe describes how, starting from matched liver and bone marrow samples, changes in erythroid, myeloid and lymphoid progenitor cell populations can be charted, and differences between samples indicate a driver of differentiation in the microenvironment.
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_erythroid-and-megakaryoblastic-leukemia-from-models-to-targeted-therapy.webp "UW Video")
⏲ 54 minutes 20 seconds 👁 310
_pure-erythroid-leukaemias.webp "Dr Montalbán Bravo meets with ecancertv at ASH 2016 to discuss the aetiology and prognostic outlook of pure erythroid leukaemia, a subset of acute leukaemia.nnHe discusses the cell lineage of the disease, and describes sequencing data helping to form a greater genetic and biological understanding of PEL and its treatment choices.nnDr Montalbán Bravo also spoke with ecancer about the clinical utility of guadecitabine and azacitadine plus verinostat.")
_evaluating-erythroid-precursors-in-patients-with-lr-mds-to-predict-response-to-esas.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 1 minute 49 seconds 👁 27
_pure-erythroid-leukaemias.webp "ecancer")
_understanding-erythropoiesis.webp "You and MDS")
_erythroid-hypoplasia-3.webp "Katie Boes")
_new-therapies-for-transfusion-dependent-mds-patients.webp "Dr Alan List speaks to ecancer at ASH 2018 about new therapies for transfusion dependent myelodysplastic syndrome (MDS) patients.nnHe explains that treatments for lower risk MDS patients with anaemia have a short duration of response, therefore there is a need for more effective treatments. One of these is luspatercept, an erythroid maturation agent.nnDr List discusses the results of the Phase III MEDALIST trial, concluding that the use of luspatercept was very durable and that the vast majority")
_blood-part-1-true-blood-crash-course-anatomy-amp-physiology-29.webp "CrashCourse")
_erythroid-and-megakaryoblastic-leukemia-from-models-to-targeted-therapy.jpg)
_pure-erythroid-leukaemias.jpg)
_evaluating-erythroid-precursors-in-patients-with-lr-mds-to-predict-response-to-esas.jpg)
_pure-erythroid-leukaemias.jpg)
_understanding-erythropoiesis.jpg)
_erythroid-hypoplasia-3.jpg)
_new-therapies-for-transfusion-dependent-mds-patients.jpg)
_blood-part-1-true-blood-crash-course-anatomy-amp-physiology-29.jpg)
![[+]](/images/menu.gif){kind=small}